| Literature DB >> 32424111 |
Weili Zhang1, Wentao Wang2, Mei Kang3, Siying Wu3, Ya Liu3, Quanfeng Liao3, Yuling Xiao3, Ying Ma3, Yi Xie1.
Abstract
BACKGROUND Infections, especially bacterial and fungal infections, are the leading cause of high mortality after liver transplantation (LT). This research investigated the pathogenic spectrum, antimicrobial susceptibility results, and risk factors of infection and death with infection to better control such infections. MATERIAL AND METHODS A retrospective cohort study was performed, and 433 liver transplant recipients between January 2010 and December 2016 were analyzed. RESULTS We found 290 isolates of bacteria and fungi in 170 infected liver transplant patients. Significant independent risk factors for bacterial and fungal infections were prolonged hospital stay (OR 1.034, 95% CI 1.013~1.056, p=0.002), mechanical ventilation (OR 3.806, 95% CI 1.567~9.248, p=0.003), and liver failure (OR 2.659, 95% CI 1.019~6.940, p=0.046). Furthermore, postoperative MELD scores (OR 1.120, 95% CI 1.020~1.230, p=0.017) and septic shock (OR 12.000, 95% CI 1.124~128.066, p=0.003) were independent risk factors for death with infection. CRAB infection is the main pathogenic bacteria of septic shock in LT patients. CONCLUSIONS We found that 39.3% of recipients had at least 1 bacterial or fungal infection after LT. Shortening the length of hospital stay and early withdrawal of mechanical ventilation will reduce the risk of infection after LT. Patients with liver failure should be more vigilant against postoperative infection. Once an infection occurs, immediate assessment of the postoperative MELD score, early diagnosis of septic shock, and active search for pathogenic evidence for precise treatment will help improve patient prognosis. Routine screening for CRAB colonization before surgery will facilitate empirical use of effective antibiotics.Entities:
Mesh:
Substances:
Year: 2020 PMID: 32424111 PMCID: PMC7258522 DOI: 10.12659/AOT.921591
Source DB: PubMed Journal: Ann Transplant ISSN: 1425-9524 Impact factor: 1.530
Recipients’ demographic and characteristics.
| n=433 | |
|---|---|
| Age | 47 (42–54) |
| Gender | |
| Male | 358 (82.7) |
| Female | 75 (17.3) |
| Hospital staya (days) | 23.5 (17.0–34.0) |
| Years of transplantation | |
| 2010 | 62 (14.3) |
| 2011 | 51 (11.8) |
| 2012 | 43 (10.0) |
| 2013 | 55 (12.7) |
| 2014 | 61 (14.1) |
| 2015 | 58 (13.4) |
| 2016 | 103 (23.8) |
| Reasons for liver transplantation | |
| Liver cancer | |
| Hepatitis B-related | 140 (32.3) |
| Others | 77 (17.8) |
| Liver cirrhosis | |
| HBV | 75 (17.3) |
| HCV | 6 (1.4) |
| Alcoholic liver cirrhosis | 14 (3.2) |
| Cholestasis | 13 (3.0) |
| Primary biliary cirrhosis | 5 (1.2) |
| Autoimmune hepatitis | 3 (0.7) |
| Re-transplantation | 4 (0.9) |
| Wilson's disease | 3 (0.7) |
| Citrin deficiency disease | 3 (0.7) |
| Schistosomiasis liver cirrhosis | 1 (0.2) |
| Mixed | 2 (0.5) |
| Others | 20 (4.6) |
| Liver failure | |
| Hepatitis B-related | 48 (11.1) |
| Others | 19 (4.4) |
Continuous data was presented by median with interquartile range (IQR);
categorical data was presented by count and percentage.
HBV – hepatitis B virus; HCV – hepatitis C virus.
The spectrum of infection sites.
| Respiratory tract | Blood stream | Abdomen | Urine tract | Bile tract | Multiple sites | Other sites | n=290 | |
|---|---|---|---|---|---|---|---|---|
| 52 | 5 | 6 | 2 | 3 | 8 | 1 | 77 (26.6) | |
| 24 | 7 | 2 | 0 | 1 | 2 | 5 | 41 (14.1) | |
| 4 | 0 | 0 | 0 | 2 | 0 | 0 | 6 (2.1) | |
| 16 | 1 | 1 | 1 | 2 | 0 | 2 | 23 (7.9) | |
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 (0.3) | |
| 8 | 1 | 3 | 2 | 0 | 2 | 2 | 18 (6.2) | |
| 8 | 1 | 0 | 0 | 0 | 0 | 0 | 9 (3.1) | |
| 4 | 1 | 0 | 0 | 0 | 0 | 0 | 5 (0.3) | |
| 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 (0.3) | |
| 3 | 1 | 0 | 0 | 0 | 0 | 0 | 4 (1.4) | |
| 2 | 0 | 0 | 0 | 0 | 0 | 0 | 2 (0.7) | |
| 0 | 1 | 0 | 0 | 1 | 0 | 1 | 3 (1.0) | |
| 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 (0.3) | |
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 (0.3) | |
| 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 (0.3) | |
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 (0.3) | |
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 (0.3) | |
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 (0.3) | |
| 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 (0.3) | |
| 0 | 10 | 8 | 7 | 3 | 7 | 3 | 38 (13.1) | |
| 0 | 0 | 0 | 1 | 0 | 0 | 1 | 2 (0.7) | |
| 0 | 2 | 0 | 0 | 0 | 0 | 0 | 2 (0.7) | |
| 2 | 2 | 1 | 0 | 0 | 1 | 0 | 6 (2.0) | |
| Coagulase-negative | 0 | 2 | 1 | 0 | 1 | 0 | 1 | 5 (1.7) |
| 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 (0.3) | |
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 (0.3) | |
| Group G | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 (0.3) |
| Non-group A/B/D | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 (0.3) |
| 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 (0.3) | |
| 22 | 1 | 4 | 2 | 0 | 0 | 2 | 31 (10.3) | |
| 3 | 0 | 0 | 0 | 0 | 0 | 0 | 3 (1.0) | |
| 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 (0.3) | |
The pathogenic spectrum of different MELD score groups.
| MELD score <15 (n=130) | 15≤ MELD score ≤30 (n=33) | MELD score >30 (n=7) | |
|---|---|---|---|
| 50 | 25 | 2 | |
| 33 | 8 | 0 | |
| 5 | 1 | 0 | |
| 12 | 9 | 2 | |
| 1 | 0 | 0 | |
| 14 | 4 | 0 | |
| 6 | 3 | 0 | |
| 3 | 2 | 0 | |
| 1 | 0 | 0 | |
| 3 | 1 | 0 | |
| 2 | 0 | 0 | |
| 3 | 0 | 0 | |
| 1 | 0 | 0 | |
| 0 | 0 | 1 | |
| 1 | 0 | 0 | |
| 1 | 0 | 0 | |
| 1 | 0 | 0 | |
| 1 | 0 | 0 | |
| 1 | 0 | 0 | |
| 26 | 10 | 2 | |
| 2 | 0 | 0 | |
| 2 | 0 | 0 | |
| 3 | 2 | 1 | |
| Coagulase-negative | 5 | 0 | 0 |
| 1 | 0 | 0 | |
| 0 | 1 | 0 | |
| Group G | 0 | 1 | 0 |
| Non-group A/B/D | 1 | 0 | 0 |
| 1 | 0 | 0 | |
| 26 | 5 | 0 | |
| 2 | 1 | 0 | |
| 1 | 0 | 0 |
The resistance rates to antimicrobial agents.
| Ampicillin | N/A | 93.8 (15/16) | N/A | N/A |
| Cefoxitin | N/A | 50.0 | 26.7 (4/15) | N/A |
| Aztreonam | N/A | 66.7 (12/18) | 62.5 (25/40) | 61.1 (11/18) |
| Cefazolin | N/A | 100 | 94.1 (16/17) | N/A |
| Cefuroxime | N/A | 100 | 83.3 | N/A |
| Cefotetan | N/A | 0 (0/15) | 14.8 (4/27) | N/A |
| Ceftriaxone | 87.8 (65/74) | 94.1 (16/17) | 75.6 (31/41) | N/A |
| Cefotaxime | 97.4 (37/38) | 93.8 (15/16) | 80.0 (24/30) | N/A |
| Ceftizoxime | 100 (38/38) | 92.9 (13/14) | 80.0 (16/20) | 100 |
| Ceftazidime | 87.0 (47/54) | 66.7 (10/15) | 56.7 (17/30) | 43.8 (7/16) |
| Cefepime | 87.8 (65/74) | 66.7 (12/18) | 51.2 (21/41) | 43.8 (10/23) |
| ESBL (+) | — | 77.8 (14/18) | 64.7 (22/34) | — |
| Cefoperazone/sulbactam | 49.1 (26/53) | 25.0 | 45.5 (5/11) | 71.4 |
| Piperacillin/tazobactam | 86.2 (50/58) | 25.0 (4/16) | 16.2 (6/37) | 52.9 (9/17) |
| Tobramycin | 73.0 (54/74) | 29.4 (5/17) | 32.5 (13/40) | 30.4 (7/23) |
| Levofloxacin | 63.5 (47/74) | 82.4 (14/17) | 53.7 (22/41) | 39.1 (9/23) |
| Ciprofloxacin | 85.3 (64/75) | 77.8 (14/18) | 53.7 (22/41) | 47.8 (11/23) |
| Cotrimoxazole | 72.2 (52/72) | 82.4 (14/17) | 65.0 (26/40) | N/A |
| Amikacin | 52.3 (34/65) | 0 (0/18) | 12.5 (5/40) | 21.7 (5/23) |
| Gentamicin | 81.1 (60/74) | 52.9 (9/17) | 61.0 (25/41) | 30.4 (7/23) |
| Meropenem | 75.0 (18/24) | 0 | 20.0 (5/25) | 28.6 |
| Ertapenem | N/A | 0 (0/16) | 16.2 (6/37) | N/A |
| Imipenem | 86.5 (64/74) | 0 (0/17) | 14.6 (6/41) | 60.9 (14/23) |
| Polymyxin B | 0 (0/40) | 0 | 0 | 25.0 |
| Tigecycline | 7.3 (3/41) | 0 | 14.3 (2/14) | N/A |
| Minocycline | 28.6 (10/35) | 0 | 40.0 (4/10) | N/A |
Total case number was less than 10;
the bacteria is naturally resistant to this antibiotic.
The risk factors of infection for recipients after LT.
| Risk factors for infection | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|
| Infection group (n=170) | Non-infection group (n=263) | OR | 95% CI | |||
| Age (years), mean±SD | 49.32±11.60 | 46.64±9.36 | 0.012 | 1.333 | 0.966~1.840 | 0.080 |
| Female | 24.1 (41/170) | 12.9 (34/263) | <0.001 | 1.174 | 0.467~2.950 | 0.733 |
| Albumin (g/L), mean±SD | 31.99±4.53 | 32.02±4.46 | 0.947 | |||
| Blood loss during operation (ml), median (IQR) | 1500 (800–3000) | 1000 (800–2000) | 0.029 | 1.107 | 0.989~1.046 | 0.226 |
| Transfusions during operation | ||||||
| Transfusions packed RBC (U), median (IQR) | 8 (4–12) | 5 (2–9) | 0.004 | 1.004 | 0.986~1.023 | 0.658 |
| Transfusion FFP (ml), median (IQR) | 875 (400–1600) | 750 (313–1150) | 0.026 | 1.011 | 0.941~1.085 | 0.772 |
| Transfusion autologous RBC,% (n) | 42,3 (44/104) | 40.3 (58/144) | 0.749 | |||
| Transfusion Platelet,%(n) | 9.6 (10/104) | 7.6 (10/145) | 0.570 | |||
| Transfusion Cryoprecipitate,% (n) | 25 (26/104) | 17 (25/144) | 0.142 | |||
| Total transfusion(ml), median (IQR) | 2775 (1625–4763) | 1900 (775–3588) | <0.001 | 1.102 | 0.978~1.048 | 0.477 |
| Hospital stay (days), median (IQR) | 26 (19–43) | 21 (16–29) | <0.001 | 1.034 | 1.013~1.056 | 0.002 |
| Postoperative MELD scores, median (IQR) | 7 (2–15) | 4 (2–7) | <0.001 | 1.014 | 0.969~1.062 | 0.545 |
| Underlying liver disease,% (n) | ||||||
| Viral cirrhosis | 18. 8 (32/170) | 17.5 (46/263) | 0.724 | |||
| Alcoholic cirrhosis | 3.5 (6/170) | 3.8 (10/263) | 0.883 | |||
| Autoimmune liver disease | 2.4 (4/170) | 1.5 (4/263) | 0.530 | |||
| Metabolic disorders | 2.4 (4/170) | 0.8 (2/263) | 0.166 | |||
| Liver cancer | 36.5 (62/170) | 58.9 (155/263) | <0.001 | 0.644 | 0.290~1.429 | 0.279 |
| Liver failure | 25.3 (43/170) | 9.1 (24/263) | <0.001 | 2.659 | 1.019~6.940 | 0.046 |
| Others | 10.6 (18/170) | 8.4 (22/263) | 0.435 | |||
| Mechanical ventilation ≥3 days, % (n) | 39.4 (67/170) | 9.5 (25/263) | <0.001 | 3.806 | 1.567~9.248 | 0.003 |
| Urinary catheterization ≥3 days, % (n) | 83.5 (142/170) | 69.6 (183/263) | 0.001 | 1.030 | 0.385~2.758 | 0.953 |
| Arteriovenous catheterization ≥3 days, % (n) | 62.4 (106/170) | 50.2 (132/263) | 0.013 | 1.013 | 0.501~2.047 | 0.972 |
OR value corresponding to per 10 unit change of variable;
OR value corresponding to per 100 unit change of variable.
The risk factors for death with infection after LT.
| Risk factors for death with infection | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|
| Death (n=26) | Survival (n=144) | OR | 95% CI | |||
| Age (years), mean±SD | 50.23±10.08 | 49.15±11.87 | 0.664 | |||
| Female | 46.2 (12/26) | 20.1 (29/144) | 0.004 | 3.755 | 0.555~25.384 | 0.175 |
| Albumin (g/L), mean±SD | 32.80±4.56 | 31.85±4.53 | 0.336 | |||
| Blood loss during operation (ml), median (IQR) | 2000 (1350–3750) | 1500 (800–2500) | 0.016 | 1.008 | 0.935~1.088 | 0.832 |
| Transfusions during operation | ||||||
| Transfusions packed RBC (IU), median (IQR) | 11 (7–16) | 7 (4–10) | 0.015 | 1.081 | 0.837~1.396 | 0.549 |
| Transfusion FFP (ml), median (IQR) | 1375 (713–1600) | 800 (400–1600) | 0.159 | |||
| Transfusion autologous RBC, % (n) | 50.0 (8/16) | 40.9 (36/88) | 0.498 | |||
| Transfusion platelet, %( n) | 0 (0/16) | 11.4 (10/88) | 0.156 | |||
| Transfusion Cryoprecipitate, % (n) | 18.8 (3/16) | 26.1 (23/88) | 0.530 | |||
| Total transfusion (ml), median (IQR) | 4150 (2875–6075) | 2575 (1475–4500) | 0.040 | 1.012 | 0.913~1.123 | 0.816 |
| Postoperative MELD score, median (IQR) | 19 (10–26) | 6 (1–12) | <0.001 | 1.120 | 1.020~1.230 | 0.017 |
| Underlying liver disease,% (n) | ||||||
| Viral cirrhosis | 23.1 (6/26) | 18.1 (26/144) | 0.547 | |||
| Alcoholic cirrhosis | 3.8 (1/26) | 3.5 (5/144) | 0.924 | |||
| Autoimmune liver disease | 3.8 (1/26) | 2.1 (3/144) | 0.585 | |||
| Metabolic disorders | 0 (0/26) | 2.8 (4/144) | 0.390 | |||
| Liver cancer | 34.6 (9/26) | 36.8 (53/144) | 0.831 | |||
| Liver failure | 19.2 (5/26) | 26.4 (38/144) | 0.440 | |||
| Others | 15.4 (4/26) | 9.7 (14/144) | 0.388 | |||
| Septic shock, % (n) | 61.5 (16/26) | 5.6 (8/144) | <0.001 | 12.000 | 1.124~128.066 | 0.040 |
| Multi-site infection, % (n) | 58.3 (14/24) | 33.9 (39/115) | 0.025 | 2.582 | 0.240~27.778 | 0.434 |
| Multi-pathogen infection, % (n) | 50.0 (12/24) | 53.0 (61/115) | 0.786 | |||
| Mechanical ventilation ≥3 days, % (n) | 75.4 (17/26) | 34.7 (50/144) | 0.003 | 1.201 | 0.188~7.684 | 0.846 |
| Urinary catheterization ≥3 days, % (n) | 96.2 (25/26) | 81.2 (117/144) | 0.059 | |||
| Arteriovenous catheterization ≥3 days, % (n) | 65.4 (17/26) | 61.8 (89/144) | 0.729 | |||
Fisher’s exact test;
OR value corresponding to per 10 unit change of variable;
OR value corresponding to per 100 unit change of variable.
Clinical data of 16 septic shock patients in the death with infection group.
| Number | Age (years) | Sex | Underlying liver disease | MELD score | Pathogens | Antimicrobial agents and duration(days) |
|---|---|---|---|---|---|---|
| 1 | 54 | Female | Hepatitis B, cirrhosis | 16 | Cefoperazone/sulbactam (7); Imipenem (5); Ciprofloxacin (7); Voriconazole (6); Vancomycin (1) | |
| 2 | 45 | Female | Autoimmune hepatitis | 23 | Enterococcus faecium (UTI), CRAB (Pneumonia) | Cefoperazone/sulbactam (13); Tigecycline (3) |
| 3 | 45 | Female | Polycystic liver | 40 | – | Imipenem (1) |
| 4 | 45 | Female | Cholestatic cirrhosis | 6 | CRAB (BSI) | Piperacillin/tazobatam (7); Cefoperazone/sulbactam (2); Imipenem (2); Voriconazole (4); Vancomycin (2) |
| 5 | 27 | Male | HCC, hepatitis B-related | 37 | Cefoperazone/sulbactam (8); Piperacillin/tazobatam (1); Imipenem (1) | |
| 6 | 61 | Female | Hepatitis B, cirrhosis | 10 | Cefoperazone/sulbactam (5); Vancomycin (1) | |
| 7 | 62 | Male | Hepatitis B, cirrhosis | 21 | CRAB, | Cefoperazone/sulbactam (16); Imipenem (13); Levofloxacin (5); Voriconazole (9) |
| 8 | 50 | Male | Hepatitis B, cirrhosis | 10 | CRAB (BSI and Pneumonia), | Cefoperazone/sulbactam (22); Ciprofloxacin (7); Vancomycin (2); Imipenem (9); Voriconazole (4); Piperacillin/tazobactam (1) |
| 9 | 46 | Male | Alcoholic cirrhosis | 25 | CRAB (BSI) | Cefoperazone/sulbactam (8); Imipenem (3) |
| 10 | 47 | Male | HCC, hepatitis B-related | 7 | – | Cefoperazone/sulbactam (12); Imipenem (6); Vancomycin (1); Piperacillin/tazobactam (1) |
| 11 | 58 | Female | Hepatitis C, cirrhosis | 19 | CRAB (SBP and Pneumonia) | Cefoperazone/sulbactam (10); Imipenem (1) |
| 12 | 65 | Male | HCC, hepatitis B-related | 6 | CRAB (BSI and Pneumonia) | Piperacillin/tazobatam (10); Imipenem (1); Vancomycin (1); Cefoperazone/sulbactam (2) |
| 13 | 56 | Male | Alcoholic cirrhosis | 22 | CRAB (BSI and Pneumonia) | |
| 14 | 37 | Male | HCC, hepatitis B-related | 26 | CRAB (Pneumonia) | Micafungin (2) |
| 15 | 56 | Male | Liver failure, hepatitis B-related | 19 | CRAB and | Cefminox (1); Meropenem (3); Caspofungin (1); Cefoperazone/sulbactam (1); Linezolid (1) |
| 16 | 41 | Male | HCC | 36 | CRAB (Pneumonia), | Cefoperazone/sulbactam (9); Imipenem (6); Micafungin (5); |
CRAB – carbapenem resistant Acinetobacter baumannii; HCC – hepatocellular carcinoma; UTI – urinary tract infection; BSI – blood stream infection; SBP – spontaneous bacterial peritonitis.